晚期口腔癌的新辅助化疗。

IF 503.1 1区 医学 Q1 ONCOLOGY CA: A Cancer Journal for Clinicians Pub Date : 2024-02-08 DOI:10.3322/caac.21829
Dan Yaniv MD, Tanguy Y. Seiwert MD, Danielle N. Margalit MD, MPH, Michelle D. Williams MD, Carly E. A. Barbon PhD, Rene D. Largo MD, Jon A. Smith, Neil D. Gross MD
{"title":"晚期口腔癌的新辅助化疗。","authors":"Dan Yaniv MD,&nbsp;Tanguy Y. Seiwert MD,&nbsp;Danielle N. Margalit MD, MPH,&nbsp;Michelle D. Williams MD,&nbsp;Carly E. A. Barbon PhD,&nbsp;Rene D. Largo MD,&nbsp;Jon A. Smith,&nbsp;Neil D. Gross MD","doi":"10.3322/caac.21829","DOIUrl":null,"url":null,"abstract":"<p>Tanguy Y. Seiwert reports personal/consulting fees from AstraZeneca, EISAI INC., Inate Pharma Inc., iTeos, Merck, Regeneron Pharmaceuticals, Sanofi, and Vir; and service on a Data and Safety Monitoring Board at BioNTech outside the submitted work. Michelle D. Williams reports personal/consulting fees from Bayer Healthcare and support for other professional activities from Springer outside the submitted work. Neil D. Gross reports grants/contracts and personal/consulting fees from Regeneron Pharmaceuticals Inc.; personal/consulting fees from DragonFly Therapeutics Inc., Intuitive Surgical Inc., Merck, Replimune, and Sanofi/Genzyme US Companies; and support for other professional activities from PDS Biotechnology Corporation outside the submitted work. The remaining authors disclosed no conflicts of interest.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":null,"pages":null},"PeriodicalIF":503.1000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21829","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant chemotherapy for advanced oral cavity cancer\",\"authors\":\"Dan Yaniv MD,&nbsp;Tanguy Y. Seiwert MD,&nbsp;Danielle N. Margalit MD, MPH,&nbsp;Michelle D. Williams MD,&nbsp;Carly E. A. Barbon PhD,&nbsp;Rene D. Largo MD,&nbsp;Jon A. Smith,&nbsp;Neil D. Gross MD\",\"doi\":\"10.3322/caac.21829\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Tanguy Y. Seiwert reports personal/consulting fees from AstraZeneca, EISAI INC., Inate Pharma Inc., iTeos, Merck, Regeneron Pharmaceuticals, Sanofi, and Vir; and service on a Data and Safety Monitoring Board at BioNTech outside the submitted work. Michelle D. Williams reports personal/consulting fees from Bayer Healthcare and support for other professional activities from Springer outside the submitted work. Neil D. Gross reports grants/contracts and personal/consulting fees from Regeneron Pharmaceuticals Inc.; personal/consulting fees from DragonFly Therapeutics Inc., Intuitive Surgical Inc., Merck, Replimune, and Sanofi/Genzyme US Companies; and support for other professional activities from PDS Biotechnology Corporation outside the submitted work. The remaining authors disclosed no conflicts of interest.</p>\",\"PeriodicalId\":137,\"journal\":{\"name\":\"CA: A Cancer Journal for Clinicians\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":503.1000,\"publicationDate\":\"2024-02-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21829\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CA: A Cancer Journal for Clinicians\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.3322/caac.21829\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21829","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Tanguy Y. Seiwert 报告了阿斯利康、EISAI INC.、Inate Pharma Inc.米歇尔-D-威廉姆斯(Michelle D. Williams)报告了拜耳医药保健公司(Bayer Healthcare)提供的个人/咨询费,以及斯普林格公司(Springer)在所提交工作之外提供的其他专业活动支持。Neil D. Gross报告了Regeneron Pharmaceuticals Inc.的资助/合同和个人/咨询费;DragonFly Therapeutics Inc.、Intuitive Surgical Inc.、Merck、Replimune和Sanofi/Genzyme US Companies的个人/咨询费;以及PDS Biotechnology Corporation对提交工作之外的其他专业活动的支持。其余作者未披露任何利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Neoadjuvant chemotherapy for advanced oral cavity cancer

Tanguy Y. Seiwert reports personal/consulting fees from AstraZeneca, EISAI INC., Inate Pharma Inc., iTeos, Merck, Regeneron Pharmaceuticals, Sanofi, and Vir; and service on a Data and Safety Monitoring Board at BioNTech outside the submitted work. Michelle D. Williams reports personal/consulting fees from Bayer Healthcare and support for other professional activities from Springer outside the submitted work. Neil D. Gross reports grants/contracts and personal/consulting fees from Regeneron Pharmaceuticals Inc.; personal/consulting fees from DragonFly Therapeutics Inc., Intuitive Surgical Inc., Merck, Replimune, and Sanofi/Genzyme US Companies; and support for other professional activities from PDS Biotechnology Corporation outside the submitted work. The remaining authors disclosed no conflicts of interest.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
873.20
自引率
0.10%
发文量
51
审稿时长
1 months
期刊介绍: CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.
期刊最新文献
Bilateral mastectomy may not reduce mortality risk Most young female cancer survivors are at minimal risk for obstetric problems Breast cancer statistics 2024. Breast cancer: The good, the bad, and an important call to effective risk reduction strategies. Reviewer acknowledgement 2024
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1